Standard Operating Procedure for Review of Instrument Calibration Logs in BA/BE Studies

1. Purpose

To define the procedure for reviewing instrument calibration logs to ensure that all analytical equipment used in bioanalytical studies for BA/BE trials is accurately calibrated and meets performance requirements prior to use.

2. Scope

This SOP applies to all calibration logs of critical analytical instruments including HPLC, LC-MS/MS, balances, pH meters, and centrifuges used in the bioanalytical laboratory for BA/BE studies.

3. Responsibilities

• Analyst/Technician: Performs and records calibration data in the logbook.
• QA Officer: Verifies calibration completeness and compliance with SOP.
• Lab Supervisor: Reviews calibration data for validity and signs off.

4. Accountability

The Head of the Bioanalytical Department is accountable for ensuring that no analytical activity is performed using uncalibrated or non-compliant equipment.

5. Procedure

5.1 Calibration Log Maintenance

1. Each instrument shall have a dedicated calibration logbook or electronic log (Annexure-1).
2. Logbook entries must include:
   • Calibration date
   • Parameters checked
   • Observed values
   • Acceptance range
   • Deviation (if any)
   • Initials and signature

5.2 Review Frequency

1. Review instrument calibration logs:
   • Monthly for high-frequency use instruments (e.g., LC-MS/MS)
   • Quarterly for support equipment (e.g., balances, pH meters)
2. Conduct additional reviews:
   • Before study initiation
   • During audits or inspections
   • Following any instrument malfunction

5.3 Review Process

1. Cross-check the calibration dates against due dates and SOP schedules.
2. Verify:
   • Calibration was performed within schedule
   • All parameters meet acceptance criteria
   • No data overwriting or missing entries
3. Highlight discrepancies and incomplete calibrations in the Calibration Review Summary (Annexure-2).

5.4 Handling Deviations

1. If calibration is overdue:
   • Label equipment as “Out of Service”
   • Inform the Lab Head and QA
   • Prevent usage until recalibrated
2. If calibration results are out of specification:
   • Stop equipment use
   • Log deviation in Deviation Register
   • Investigate root cause and initiate corrective actions

5.5 Documentation

1. Ensure every review entry includes:
   • Reviewer name
   • Date of review
   • Comments
   • Signature
2. Maintain reviewed logs in the equipment calibration file for 5 years.

6. Abbreviations

• BA/BE: Bioavailability/Bioequivalence
• SOP: Standard Operating Procedure
• QA: Quality Assurance
• HPLC: High-Performance Liquid Chromatography
• LC-MS/MS: Liquid Chromatography with Tandem Mass Spectrometry

7. Documents

1. Instrument Calibration Logbook – Annexure-1
2. Calibration Review Summary – Annexure-2

8. References

• ICH Q9: Quality Risk Management
• OECD GLP Principles
• 21 CFR Part 11 – Electronic Records & Signatures

9. SOP Version

Version: 2.0

10. Approval Section

11. Annexures

Annexure-1: Instrument Calibration Logbook

Annexure-2: Calibration Review Summary

Revision History:

Standard Operating Procedure for Analyst Proficiency Testing in BA/BE Studies

1. Purpose

To establish a procedure for evaluating and documenting the technical competency of analysts involved in bioanalytical activities in BA/BE studies through scheduled proficiency testing in accordance with regulatory expectations.

2. Scope

This SOP is applicable to all analysts performing bioanalytical sample preparation, extraction, analysis, integration, and documentation activities in the Bioanalytical Laboratory for BA/BE studies.

3. Responsibilities

• QA Officer: Coordinates the testing schedule and reviews results.
• Lab Manager: Assigns evaluators and approves proficiency evaluation outcomes.
• Evaluator (Senior Analyst): Monitors and scores performance during testing.
• Analyst: Participates in testing and follows protocols during evaluation.

4. Accountability

The Head of Bioanalytical Department is accountable for ensuring proficiency testing is performed consistently, and only qualified analysts perform regulated study analyses.

5. Procedure

5.1 Frequency of Proficiency Testing

1. Conduct proficiency tests:
   • Annually for all analysts
   • During onboarding of new analysts
   • After a prolonged break (>3 months) or as part of CAPA
2. Prepare a Proficiency Testing Calendar and maintain in Annexure-1.

5.2 Components of Proficiency Test

1. Test is designed to include:
   • Sample preparation (e.g., SPE, LLE)
   • Instrument operation (e.g., LC-MS/MS)
   • Chromatogram integration and peak review
   • Data documentation and raw data handling
2. Test samples are spiked with known concentrations and analyzed in blinded format.

5.3 Evaluation Criteria

1. Analyst performance is scored on:
   • Accuracy: ±15% deviation from nominal values
   • Precision: %CV ≤ 15%
   • Adherence to SOPs and GLP documentation
2. Use Annexure-2: Analyst Proficiency Scorecard for evaluation.

5.4 Documentation and Review

1. Document results, observations, and improvement recommendations in Annexure-3: Proficiency Testing Report.
2. QA reviews and signs off on reports.
3. Store reports in analyst training and competency file.

5.5 Retraining and Corrective Action

1. If an analyst fails to meet acceptance criteria:
   • Assign retraining on deficient areas
   • Repeat the proficiency test within 15 days
   • Restrict analyst from regulated studies until successful retesting
2. Document all retraining sessions and corrective actions.

6. Abbreviations

• SOP: Standard Operating Procedure
• BA/BE: Bioavailability/Bioequivalence
• QA: Quality Assurance
• CV: Coefficient of Variation
• GLP: Good Laboratory Practice

7. Documents

1. Proficiency Testing Calendar – Annexure-1
2. Analyst Proficiency Scorecard – Annexure-2
3. Proficiency Testing Report – Annexure-3

8. References

• OECD Principles of GLP
• ICH M10: Bioanalytical Method Validation
• US FDA Bioanalytical Method Validation Guidance

9. SOP Version

Version: 2.0

10. Approval Section

11. Annexures

Annexure-1: Proficiency Testing Calendar

Annexure-2: Analyst Proficiency Scorecard

Annexure-3: Proficiency Testing Report

Revision History:

Standard Operating Procedure for Change Control in Bioanalytical Method in BA/BE Studies

1. Purpose

To establish a standardized approach for initiating, assessing, documenting, and implementing changes in validated bioanalytical methods used in BA/BE studies, in compliance with ICH, US FDA, and OECD GLP guidelines.

2. Scope

This SOP applies to all proposed changes made to approved and validated bioanalytical methods used for quantitative estimation of analytes in biological matrices during BA/BE studies.

3. Responsibilities

• Analyst/Method Developer: Proposes changes and provides scientific rationale.
• QA Officer: Reviews impact assessment and ensures regulatory compliance.
• Bioanalytical Reviewer: Evaluates justification and method performance post-change.
• Bioanalytical Head: Approves final implementation and updates documentation.

4. Accountability

The Head of Bioanalytical Laboratory is accountable for ensuring that all method changes are justified, documented, verified, and approved prior to implementation.

5. Procedure

5.1 Types of Changes Requiring Control

1. Instrument configuration changes (e.g., detector, pump, column switch).
2. Reagent grade or source changes.
3. Change in sample extraction technique (e.g., LLE to SPE).
4. Modifications in mobile phase composition or flow rate.
5. Software upgrades affecting integration or calculation parameters.
6. Any parameter that impacts method performance.

5.2 Initiating Change Request

1. The analyst submits a Change Control Request (Annexure-1) detailing:
   • Current method parameters
   • Proposed changes
   • Scientific rationale
   • Supporting validation or development data
2. Assign a unique Change Control Number (e.g., BCC-025/2025).

5.3 Risk and Impact Assessment

1. The bioanalytical reviewer assesses:
   • Impact on accuracy, precision, linearity, selectivity, recovery, matrix effect
   • Potential impact on reported data and subject safety
2. Document findings in Annexure-2: Risk Impact Assessment Form.

5.4 Approval and Implementation

1. QA reviews compliance with ICH M10 and GLP guidelines.
2. The Head of Bioanalytical Lab approves or rejects the request based on risk profile and data justification.
3. Upon approval:
   • Document updated method parameters
   • Conduct partial or full revalidation as required
   • Archive supporting documents with the Change Control File

5.5 Communication and Training

1. Inform all impacted personnel via Change Notification Memo (Annexure-3).
2. Conduct targeted training before implementation.
3. Record training in the Training Logbook with employee acknowledgment.

5.6 Post-Implementation Review

1. Conduct a performance check on initial three analytical runs using updated method.
2. QA to verify that system suitability and QC acceptance are met consistently.
3. Close the change control by completing Annexure-4: Change Closure Report.

6. Abbreviations

• SOP: Standard Operating Procedure
• BA/BE: Bioavailability/Bioequivalence
• GLP: Good Laboratory Practices
• QA: Quality Assurance
• ICH: International Council for Harmonisation

7. Documents

1. Change Control Request – Annexure-1
2. Risk Impact Assessment Form – Annexure-2
3. Change Notification Memo – Annexure-3
4. Change Closure Report – Annexure-4

8. References

• ICH M10: Bioanalytical Method Validation
• OECD Principles of GLP
• US FDA Guidance for Bioanalytical Method Development

9. SOP Version

Version: 2.0

10. Approval Section

11. Annexures

Annexure-1: Change Control Request

Annexure-2: Risk Impact Assessment Form

Annexure-3: Change Notification Memo

Annexure-4: Change Closure Report

Revision History:

Standard Operating Procedure for Batch Rejection and Repeat Analysis in BA/BE Studies

1. Purpose

This SOP outlines the systematic procedure to identify criteria for rejecting analytical batches and the process to repeat the analysis, ensuring that data quality and regulatory compliance are maintained during bioanalytical evaluations in BA/BE studies.

2. Scope

This SOP applies to all bioanalytical runs performed in the quantification of drug concentrations in biological matrices like plasma, serum, or urine under BA/BE studies conducted at the bioanalytical laboratory.

3. Responsibilities

• Analyst: Performs initial batch review and flags issues requiring batch rejection.
• QA Officer: Reviews justification for rejection and ensures documentation is complete.
• Bioanalytical Reviewer: Approves repeat analysis plan and verifies data compliance post-repeat.
• Bioanalytical Head: Authorizes final decision on batch rejection and approves repeat analysis.

4. Accountability

The Bioanalytical Head is accountable for maintaining data integrity by ensuring rejected batches are properly documented and repeat analyses are justified and conducted according to applicable guidelines.

5. Procedure

5.1 Criteria for Batch Rejection

1. An analytical batch shall be rejected if:
   • QC sample failure exceeds the acceptable limits as per ICH M10 (more than 33% of total or 50% at any level).
   • Calibration curve fails to meet accuracy or linearity criteria.
   • System suitability parameters (e.g., peak shape, retention time) are out of range.
   • Chromatographic issues such as interference, co-elution, or carryover.
   • Deviation in run sequence, labeling, or sample position errors.

5.2 Documentation of Batch Rejection

1. Record rejection details in Annexure-1: Batch Rejection Log including:
   • Run ID
   • Study code
   • Date of analysis
   • Reason for rejection
   • Authorized by
2. Annotate chromatograms and data files clearly with “REJECTED” watermark and maintain in the archival file.

5.3 Planning Repeat Analysis

1. Prepare a Repeat Analysis Request Form (Annexure-2) with:
   • List of samples to be repeated
   • Justification
   • Proposed method and timeline
2. QA and Bioanalytical Head must jointly approve the repeat analysis plan before initiation.
3. Repeat analysis must use:
   • Fresh calibration and QC samples
   • Same method and validated parameters

5.4 Conduct of Repeat Analysis

1. Follow same procedures as in the original batch preparation and processing.
2. Maintain records in the Repeat Analysis Log (Annexure-3).
3. Tag repeat runs with a unique batch ID and reference original run ID.

5.5 Review and Reporting

1. Compare original and repeat results and justify any variation in values exceeding ±20%.
2. Include repeat run data in the bioanalytical report with annotations and explanation for original run failure.
3. Ensure that the final reported result is from the repeat batch unless otherwise justified.

6. Abbreviations

• BA/BE: Bioavailability/Bioequivalence
• SOP: Standard Operating Procedure
• QC: Quality Control
• QA: Quality Assurance
• ICH: International Council for Harmonisation

7. Documents

1. Batch Rejection Log – Annexure-1
2. Repeat Analysis Request Form – Annexure-2
3. Repeat Analysis Log – Annexure-3

8. References

• ICH M10 Bioanalytical Method Validation Guideline
• FDA Guidance on Bioanalytical Method Validation (2022)
• OECD GLP Principles

9. SOP Version

Version: 2.0

10. Approval Section

11. Annexures

Annexure-1: Batch Rejection Log

Annexure-2: Repeat Analysis Request Form

Annexure-3: Repeat Analysis Log

Revision History:

Standard Operating Procedure for Run Acceptance Criteria and Review in BA/BE Studies

1. Purpose

To define the acceptance criteria for bioanalytical runs and outline the procedure for run review and approval to ensure data integrity and compliance with ICH, FDA, and WHO bioanalytical guidelines.

2. Scope

This SOP applies to all analytical runs generated during the quantification of drug/analyte concentrations in biological matrices for bioavailability/bioequivalence (BA/BE) studies.

3. Responsibilities

• Analyst: Prepares and processes the run and reviews raw data for compliance with acceptance criteria.
• QA Personnel: Reviews the final data and flags any anomalies or deviations.
• Bioanalytical Reviewer: Performs second-level review of integration and calculates precision/accuracy values.
• Bioanalytical Head: Approves the analytical run and determines acceptability for reporting.

4. Accountability

The Head of the Bioanalytical Department is accountable for ensuring that analytical runs are conducted and reviewed according to the approved method validation and regulatory requirements.

5. Procedure

5.1 Pre-Run Setup and Controls

1. Verify that the instrument is calibrated and meets system suitability criteria.
2. Prepare calibration standards, quality control (QC) samples, and blank samples according to the validated method.
3. Document the run sequence, including sample positions and file names in the Run Sequence Log (Annexure-1).

5.2 Acceptance Criteria for Calibration Curve

1. At least 75% of non-zero calibrators, including the lowest and highest, must meet the acceptance criteria:
   • Nominal concentration ±15% (±20% for LLOQ)
2. Regression coefficient (r²) should be ≥ 0.98.
3. Evaluate back-calculated concentrations of standards for compliance.

5.3 Quality Control (QC) Sample Acceptance Criteria

1. At least 67% of QC samples should meet ±15% of their nominal concentrations.
2. At least 50% of QC samples at each level (LQC, MQC, HQC) must be within ±15%.
3. Reject the entire run if QC fails to meet the above criteria.

5.4 Run Review Process

1. Perform chromatogram integration using predefined integration parameters.
2. Review each chromatogram for:
   • Retention time consistency
   • Peak shape and area
   • Baseline noise or interference
3. Document observations in the Run Review Checklist (Annexure-2).

5.5 Reinjection and Partial Reanalysis

1. If a sample chromatogram is abnormal:
   • Justify reinjection based on SOP criteria
   • Document the reason and outcome in the Reinjection Log (Annexure-3)
2. Partial reanalysis is allowed if approved by QA and documented appropriately.

5.6 Approval and Documentation

1. Only QA-reviewed and authorized runs are acceptable for final reporting.
2. Each run must be signed off by the analyst, reviewer, QA, and bioanalytical head.
3. Attach run data, chromatograms, and review forms to the Study Master File (SMF).

6. Abbreviations

• SOP: Standard Operating Procedure
• BA/BE: Bioavailability/Bioequivalence
• LLOQ: Lower Limit of Quantification
• QC: Quality Control
• SMF: Study Master File

7. Documents

1. Run Sequence Log – Annexure-1
2. Run Review Checklist – Annexure-2
3. Reinjection Log – Annexure-3

8. References

• ICH M10: Bioanalytical Method Validation
• US FDA Guidance for Industry – Bioanalytical Method Validation (2022)
• OECD GLP Principles

9. SOP Version

Version: 2.0

10. Approval Section

11. Annexures

Annexure-1: Run Sequence Log

Annexure-2: Run Review Checklist

Annexure-3: Reinjection Log

Revision History:

Standard Operating Procedure for Ensuring Sample Integrity Before Bioanalytical Analysis in BA/BE Studies

1. Purpose

To define the procedures to be followed for verifying and ensuring the physical and analytical integrity of biological samples (e.g., plasma, serum) before conducting bioanalytical evaluations in BA/BE studies.

2. Scope

This SOP is applicable to all biological samples received, stored, and prepared for bioanalysis in the bioanalytical laboratory of BA/BE studies.

3. Responsibilities

• Analyst: Inspects and evaluates each sample’s condition before processing.
• Sample Custodian: Retrieves and verifies samples against the log.
• QA Representative: Verifies documentation and reviews deviations.
• Lab Manager: Authorizes sample rejection or reprocessing as required.

4. Accountability

The Head of the Bioanalytical Department is accountable for ensuring sample quality verification before analysis and for maintaining accurate integrity records.

5. Procedure

5.1 Sample Retrieval from Storage

1. Retrieve samples based on the Sample Analysis Plan and Sample Inventory Sheet.
2. Document retrieval date, time, and analyst in Annexure-1: Sample Movement Log.

5.2 Visual Inspection

1. Inspect each sample vial for:
   • Label integrity (study code, subject ID, time point)
   • Frosting or condensation on vials
   • Leakage, breakage, discoloration, or particulate matter
2. Document any discrepancies in Annexure-2: Sample Integrity Check Form.

5.3 Thawing and Equilibration

1. Thaw samples at 4°C or as per method SOP, avoiding repeated freeze-thaw cycles.
2. Mix gently by inversion or vortexing to homogenize contents before analysis.
3. Do not use samples exhibiting signs of hemolysis or phase separation unless justified and documented.

5.4 Temperature and Storage Condition Review

1. Review freezer log entries for temperature maintenance throughout storage period.
2. If any temperature excursions occurred, check associated CAPA and QA approval before proceeding.
3. Verify sample batch storage mapping from Annexure-3: Freezer Inventory Sheet.

5.5 Sample Qualification for Analysis

1. Only samples that meet the following criteria qualify for analysis:
   • Properly labeled and sealed
   • No visual defects or contamination
   • Maintained within validated temperature range
2. Segregate and label rejected samples with “Not for Analysis” and document in Annexure-4: Rejected Sample Log.
3. Notify Study Manager and QA for confirmation and further instruction.

5.6 Documentation

1. All forms must be signed by the analyst and reviewed by QA before start of analysis.
2. Attach integrity forms to the Study Master File (SMF).
3. Retain all integrity records for at least 5 years or as per sponsor-specific retention policy.

6. Abbreviations

• BA/BE: Bioavailability/Bioequivalence
• SOP: Standard Operating Procedure
• QA: Quality Assurance
• SMF: Study Master File

7. Documents

1. Sample Movement Log – Annexure-1
2. Sample Integrity Check Form – Annexure-2
3. Freezer Inventory Sheet – Annexure-3
4. Rejected Sample Log – Annexure-4

8. References

• ICH M10: Bioanalytical Method Validation
• US FDA Bioanalytical Method Guidance (2022)
• OECD GLP Principles

9. SOP Version

Version: 2.0

10. Approval Section

11. Annexures

Annexure-1: Sample Movement Log

Annexure-2: Sample Integrity Check Form

Annexure-3: Freezer Inventory Sheet

Annexure-4: Rejected Sample Log

Revision History:

Standard Operating Procedure for Documentation of Sample Storage Conditions in BA/BE Studies

1. Purpose

To define the procedure for documenting and maintaining the storage conditions of biological samples such as plasma, serum, and urine during BA/BE studies to ensure sample integrity and compliance with regulatory requirements.

2. Scope

This SOP applies to all biological samples stored in freezers or refrigerators at the bioanalytical facility throughout the duration of BA/BE studies.

3. Responsibilities

• Sample Custodian: Ensures sample storage conditions are monitored and documented.
• QA Personnel: Reviews storage logs and validates compliance during internal audits.
• Lab Technicians: Monitor temperatures and notify for excursions.
• Bioanalytical Head: Ensures SOP adherence and CAPA implementation when required.

4. Accountability

The Head of the Bioanalytical Department is accountable for maintaining compliant and auditable records of sample storage conditions for all biological samples.

5. Procedure

5.1 Designated Storage Areas

1. Samples are stored in designated:
   • Deep freezers (-70°C or lower)
   • Freezers (-20°C)
   • Refrigerators (2–8°C)
2. Each unit must have a unique identifier (e.g., FZ-001, RF-002).

5.2 Temperature Monitoring Devices

1. Equip each unit with a calibrated temperature data logger or digital thermometer.
2. Devices must be:
   • Calibrated annually
   • Placed at the center or most critical zone
3. Attach display readers outside for quick visual check.

5.3 Documentation of Temperature

1. Record temperatures twice daily (start and end of shift) in Annexure-1: Sample Storage Temperature Log.
2. Entries must include:
   • Date and time
   • Storage unit ID
   • Temperature (°C)
   • Initials of personnel
3. Print and archive logger graphs weekly in a binder specific to each unit.

5.4 Handling Temperature Excursions

1. If temperature is out of acceptable range:
   • Label the storage unit as “Under Observation.”
   • Move samples to backup storage.
   • Document excursion in Annexure-2: Temperature Excursion Log.
   • Inform QA immediately.
2. Initiate CAPA as needed and document resolution.

5.5 Backup Power and Alarm Systems

1. Ensure:
   • Uninterrupted Power Supply (UPS) or generator support is available.
   • Freezer units are connected to temperature alarms with 24×7 alert notification.

5.6 Sample Inventory Mapping

1. Each freezer must maintain an updated Sample Inventory Sheet (Annexure-3).
2. Include:
   • Study code
   • Rack and box number
   • Sample IDs and date of placement
3. Reconcile inventory monthly with receipt logs.

6. Abbreviations

• SOP: Standard Operating Procedure
• QA: Quality Assurance
• UPS: Uninterrupted Power Supply
• CAPA: Corrective and Preventive Action
• °C: Degrees Celsius

7. Documents

1. Sample Storage Temperature Log – Annexure-1
2. Temperature Excursion Log – Annexure-2
3. Sample Inventory Sheet – Annexure-3

8. References

• ICH GCP E6(R2)
• OECD GLP Principles
• 21 CFR Part 58 – FDA GLP Regulations

9. SOP Version

Version: 2.0

10. Approval Section

11. Annexures

Annexure-1: Sample Storage Temperature Log

Annexure-2: Temperature Excursion Log

Annexure-3: Sample Inventory Sheet

Revision History:

Standard Operating Procedure for Logging Receipt of Samples from Clinical Site in BA/BE Studies

1. Purpose

To establish a standardized procedure for receiving, inspecting, and logging biological samples such as plasma or serum received from the clinical site to the bioanalytical laboratory in bioavailability/bioequivalence (BA/BE) studies.

2. Scope

This SOP applies to all biological sample shipments from the clinical unit to the bioanalytical facility for analysis during BA/BE studies conducted at [Organization Name].

3. Responsibilities

• Sample Custodian: Receives, verifies, and logs samples upon arrival.
• Courier Personnel: Delivers samples and provides signed transport documents.
• Bioanalytical QA: Verifies chain-of-custody and compliance with transport conditions.
• Bioanalytical Head: Ensures procedures are followed and discrepancies resolved.

4. Accountability

The Bioanalytical Department Head is accountable for ensuring that the receipt and documentation of clinical samples meet GCP and GLP requirements, and that sample integrity is maintained.

5. Procedure

5.1 Pre-Arrival Notification

1. Clinical site staff informs the receiving lab at least 2 hours before sample shipment.
2. Details to be shared:
   • Study Code
   • No. of Samples
   • Shipment Date & Time
   • Courier Name & Tracking
3. Receiving team ensures freezer space and staff readiness.

5.2 Receipt of Samples

1. Upon arrival:
   • Check external condition of container (no leakage, breakage, tampering).
   • Record ambient temperature if temperature logger is provided.
2. Accept the consignment only if:
   • Seal is intact
   • Temperature maintained as per requirement (e.g., ≤ −20°C)
3. Sign off the Sample Transfer Form provided by courier (Annexure-1).

5.3 Verification of Sample Details

1. Open container in designated receiving area using PPE.
2. Cross-check sample labels with the Sample Inventory Sheet provided by the clinical site.
3. Verify:
   • Subject ID
   • Time point
   • Number of vials
   • Sample condition (intact label, no leakage/frosting)
4. Document discrepancies in Annexure-2: Sample Receipt and Verification Log.

5.4 Logging and Storage

1. Assign a Sample Receipt Log ID to the consignment.
2. Record all sample details in the Sample Receipt Log Book (Annexure-3).
3. Transfer samples to appropriate freezer (−20°C or −70°C).
4. Label storage rack with:
   • Study Code
   • Receipt Date
   • Freezer Number

5.5 Reporting and Resolution

1. Notify clinical site and QA of:
   • Missing samples
   • Unlabeled/partially labeled vials
   • Improper temperature on arrival
2. Complete a Sample Receipt Deviation Form if any issues are found (Annexure-4).
3. All forms and logs must be signed and archived in the Study Master File (SMF).

6. Abbreviations

• BA/BE: Bioavailability/Bioequivalence
• SOP: Standard Operating Procedure
• QA: Quality Assurance
• SMF: Study Master File

7. Documents

1. Sample Transfer Form – Annexure-1
2. Sample Receipt and Verification Log – Annexure-2
3. Sample Receipt Log Book – Annexure-3
4. Sample Receipt Deviation Form – Annexure-4

8. References

• ICH GCP E6(R2)
• US FDA Bioanalytical Method Validation Guidance (2022)
• GLP Guidelines – OECD 14

9. SOP Version

Version: 2.0

10. Approval Section

11. Annexures

Annexure-1: Sample Transfer Form

Annexure-2: Sample Receipt and Verification Log

Annexure-3: Sample Receipt Log Book

Annexure-4: Sample Receipt Deviation Form

Revision History:

Standard Operating Procedure for Disposal of Used Biological Samples in BA/BE Studies

1. Purpose

To define the procedure for the safe, ethical, and regulatory-compliant disposal of used biological samples, such as blood, plasma, serum, and urine, after completion of analysis in bioavailability and bioequivalence (BA/BE) studies.

2. Scope

This SOP applies to all biological samples collected, stored, and analyzed during BA/BE studies at the bioanalytical facility, which are no longer required for reanalysis, stability studies, or audit purposes.

3. Responsibilities

• Bioanalytical Scientist: Identifies samples eligible for disposal and documents disposal request.
• Lab Technician: Carries out physical disposal following biosafety and environmental regulations.
• QA Officer: Reviews disposal records and ensures compliance with applicable guidelines.
• Facility Manager: Ensures coordination with biomedical waste disposal vendors.

4. Accountability

The Head of the Bioanalytical Department is accountable for ensuring that all used biological samples are disposed of safely and in accordance with SOPs and regulatory requirements.

5. Procedure

5.1 Identification of Samples for Disposal

1. Samples eligible for disposal include:
   • Samples beyond the reanalysis period (typically 3 months after study report finalization)
   • Samples declared non-usable due to stability loss or contamination
2. The study scientist generates a Sample Disposal Request Form (Annexure-1) and submits it to QA for approval.

5.2 Approval and Documentation

1. QA reviews:
   • Study closure documentation
   • Audit or reanalysis status
   • Regulatory retention period
2. Upon confirmation, QA signs off the Sample Disposal Request Form.
3. Disposal is documented in the Biological Sample Disposal Log (Annexure-2).

5.3 Segregation and Handling

1. Samples for disposal are segregated in biohazard bags or puncture-proof containers labeled “For Disposal.”
2. Frozen samples are thawed in a designated biosafety area.
3. Personnel must wear gloves, lab coat, and protective eyewear during handling.

5.4 Disposal Method

1. Samples are disposed via:
   • Incineration in authorized biomedical waste incinerators
   • Autoclaving followed by landfill, as per local biomedical waste rules
2. Disposal must be performed in the presence of at least two witnesses (one from QA).
3. Vendor-signed disposal certificate must be obtained and attached to Annexure-2.

5.5 Compliance and Audit Readiness

1. All disposal activities must be audit-traceable.
2. Retention of logs and certificates for at least 5 years.
3. QA shall periodically review disposal practices for continuous compliance.

6. Abbreviations

• BA/BE: Bioavailability/Bioequivalence
• QA: Quality Assurance
• SOP: Standard Operating Procedure
• BMW: Biomedical Waste
• CoA: Certificate of Analysis

7. Documents

1. Sample Disposal Request Form – Annexure-1
2. Biological Sample Disposal Log – Annexure-2
3. Disposal Certificate from Authorized Vendor – Annexure-3

8. References

• Biomedical Waste Management Rules, 2016 (India)
• ICH GCP E6(R2)
• US FDA GLP Guidance for Bioanalytical Methods

9. SOP Version

Version: 2.0

10. Approval Section

11. Annexures

Annexure-1: Sample Disposal Request Form

Annexure-2: Biological Sample Disposal Log

Annexure-3: Disposal Certificate

Revision History:

Standard Operating Procedure for Verification of Mobile Phase Composition in BA/BE LC-MS/MS Analysis

1. Purpose

To establish a standard procedure for the preparation, verification, and documentation of mobile phase composition used in LC-MS/MS systems for BA/BE bioanalytical studies.

2. Scope

This SOP applies to all analysts and laboratory personnel involved in preparing and verifying mobile phases for validated LC-MS/MS methods used in BA/BE studies within the bioanalytical laboratory.

3. Responsibilities

• Analytical Scientist: Prepares mobile phase according to method-specific requirements and performs verification steps.
• QA Officer: Reviews mobile phase logs and verifies adherence to procedures.
• Lab Manager: Maintains oversight of mobile phase records and ensures compliance with this SOP.

4. Accountability

The Head of Bioanalytical Department is accountable for ensuring proper preparation, verification, and documentation of mobile phases used in regulated bioanalytical methods.

5. Procedure

5.1 Reagent and Solvent Quality

1. Use HPLC-grade solvents (e.g., acetonitrile, methanol, water) and reagents with CoA from approved vendors.
2. Ensure chemical labels clearly indicate:
   • Name and grade
   • Lot number
   • Expiry date
3. Do not use expired solvents or those with signs of contamination or precipitation.

5.2 Mobile Phase Preparation

1. Refer to validated method SOP for exact composition, order of mixing, and pH adjustment requirements.
2. Use volumetric glassware or calibrated dispensers for accurate measurement.
3. Prepare mobile phase in a clean, designated preparation area.
4. For buffered mobile phases:
   • Ensure pH is measured using a calibrated pH meter.
   • Adjust pH using approved acid/base agents only.
5. Record preparation details in Annexure-1: Mobile Phase Preparation Log.

5.3 Filtration and Degassing

1. Filter the mobile phase using 0.22 µm or 0.45 µm nylon or PVDF membrane filters (as per method).
2. Degas by sonication for at least 10 minutes or by helium sparging, if required.
3. Label final container with:
   • Mobile phase name
   • Date of preparation
   • Prepared by
   • Storage conditions
   • Expiry date (max 7 days or method-specific)

5.4 Verification of Composition

1. Verify mobile phase composition via:
   • Gravimetric check for solvent ratios (optional)
   • pH confirmation for aqueous phases
   • Retention time stability of system suitability standard
2. Record verification results in Annexure-2: Mobile Phase Verification Checklist.
3. Do not proceed with analysis if:
   • pH deviates ±0.2 units from specified range
   • Appearance is turbid or phase separation is observed

5.5 Storage and Disposal

1. Store mobile phase in clean, airtight glass bottles, preferably amber-colored for light-sensitive preparations.
2. Label containers with expiry and discard after designated time.
3. Dispose unused or expired mobile phases according to SOP for Hazardous Waste Disposal.

6. Abbreviations

• BA/BE: Bioavailability/Bioequivalence
• LC-MS/MS: Liquid Chromatography Tandem Mass Spectrometry
• pH: Hydrogen Ion Concentration
• SOP: Standard Operating Procedure
• CoA: Certificate of Analysis

7. Documents

1. Mobile Phase Preparation Log – Annexure-1
2. Mobile Phase Verification Checklist – Annexure-2

8. References

• ICH M10: Bioanalytical Method Validation
• US FDA Bioanalytical Method Validation Guidance (2022)
• USP <621> Chromatography

9. SOP Version

Version: 2.0

10. Approval Section

11. Annexures

Annexure-1: Mobile Phase Preparation Log

Annexure-2: Mobile Phase Verification Checklist

Revision History: